Cerenome is trading 6.95% down at $1.74 on October 1; healthcare-sector weakness may add pressure, but no same-day company-specific negative catalyst was identified.

  • The September 30 business update reported 222 CNSide tests and $1.55 million in unaudited third-quarter gross billings; initial cash collections are expected in Q4.
  • Cerenome projected a Q4 annualized billing run rate of approximately $10 million to $12 million.